Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TIVOZANIB for Renal cell carcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 1,258 adverse event reports in the FDA FAERS database where TIVOZANIB was used for Renal cell carcinoma.

Most Reported Side Effects for TIVOZANIB

Side Effect Reports % Deaths Hosp.
Fatigue 291 20.9% 9 36
Diarrhoea 177 12.7% 7 28
Blood pressure increased 144 10.3% 6 21
Nausea 132 9.5% 8 24
Decreased appetite 127 9.1% 7 32
Disease progression 121 8.7% 12 17
Dysphonia 109 7.8% 3 13
Death 89 6.4% 89 15
Asthenia 80 5.7% 5 17
Off label use 73 5.2% 3 8
Pain 68 4.9% 5 16
Hypertension 66 4.7% 5 12
Vomiting 63 4.5% 3 20
Dyspnoea 52 3.7% 4 22
Constipation 51 3.7% 2 14

Other Indications for TIVOZANIB

Metastatic renal cell carcinoma (49) Renal cancer (34) Product used for unknown indication (18) Clear cell renal cell carcinoma (7) Neoplasm (6)

Other Drugs Used for Renal cell carcinoma

CABOZANTINIB S-MALATE (9,156) NIVOLUMAB (6,514) LENVATINIB (3,849) PEMBROLIZUMAB (3,027) SUNITINIB MALATE (2,926) PAZOPANIB (2,799) IPILIMUMAB (2,585) AXITINIB (2,447) EVEROLIMUS (1,573) CABOZANTINIB (1,241)

Related Pages

TIVOZANIB Full Profile All Renal cell carcinoma Drugs TIVOZANIB Demographics TIVOZANIB Timeline